Adenocarcinoma in Situ - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Adenocarcinoma in Situ

The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform

Theo J M Helmerhorst – 1st expert on this subject based on the ideXlab platform

  • Conservative Treatment Seems the Best Choice in Adenocarcinoma in Situ of the Cervix Uteri.
    Journal of Lower Genital Tract Disease, 2020
    Co-Authors: Astrid Baalbergen, Anco Molijn, Wim Quint, Frank Smedts, Theo J M Helmerhorst

    Abstract:

    ObjectiveTo study diagnostic and therapeutic strategies, outcomes, and follow-up in a large series of women with Adenocarcinoma in Situ (AIS) of the uterine cervix and investigate if human papillomavirus (HPV) typing among women with negative cytology reports would have helped with early AIS detecti

  • Adenocarcinoma in Situ of the uterine cervix a systematic review
    International Journal of Gynecological Cancer, 2014
    Co-Authors: Astrid Baalbergen, Theo J M Helmerhorst

    Abstract:

    Objective This study aimed to review literature if therapeutic strategies in Adenocarcinoma in Situ of the cervix could lead to a more conservative approach. Methods A review of the literature was conducted using a Medline search for articles published between 1966 and 2013. Results Thirty-five studies showed that after a radical cone, 16.5% residual disease in the re-cone or uterus was found. After cone with positive margins, residual abnormalities were found in 49.3%. Thirty-seven studies showed 5% recurrence rate after conservative therapy (large loop excision transformation zone–cold knife conization. After conization with negative margins, the risk of recurrence was 3%. Conclusions Adenocarcinoma in Situ is a relatively rare premalignant but increasingly frequent lesion of the cervix. Although there is a risk of relapse (3%) with a chance of malignancy (

Astrid Baalbergen – 2nd expert on this subject based on the ideXlab platform

  • Conservative Treatment Seems the Best Choice in Adenocarcinoma in Situ of the Cervix Uteri.
    Journal of Lower Genital Tract Disease, 2020
    Co-Authors: Astrid Baalbergen, Anco Molijn, Wim Quint, Frank Smedts, Theo J M Helmerhorst

    Abstract:

    ObjectiveTo study diagnostic and therapeutic strategies, outcomes, and follow-up in a large series of women with Adenocarcinoma in Situ (AIS) of the uterine cervix and investigate if human papillomavirus (HPV) typing among women with negative cytology reports would have helped with early AIS detecti

  • Adenocarcinoma in Situ of the uterine cervix a systematic review
    International Journal of Gynecological Cancer, 2014
    Co-Authors: Astrid Baalbergen, Theo J M Helmerhorst

    Abstract:

    Objective This study aimed to review literature if therapeutic strategies in Adenocarcinoma in Situ of the cervix could lead to a more conservative approach. Methods A review of the literature was conducted using a Medline search for articles published between 1966 and 2013. Results Thirty-five studies showed that after a radical cone, 16.5% residual disease in the re-cone or uterus was found. After cone with positive margins, residual abnormalities were found in 49.3%. Thirty-seven studies showed 5% recurrence rate after conservative therapy (large loop excision transformation zone–cold knife conization. After conization with negative margins, the risk of recurrence was 3%. Conclusions Adenocarcinoma in Situ is a relatively rare premalignant but increasingly frequent lesion of the cervix. Although there is a risk of relapse (3%) with a chance of malignancy (

Colin J.r. Stewart – 3rd expert on this subject based on the ideXlab platform

  • hpv negative gastric type Adenocarcinoma in Situ of the cervix a spectrum of rare lesions exhibiting gastric and intestinal differentiation
    The American Journal of Surgical Pathology, 2017
    Co-Authors: Karen L Talia, Colin J.r. Stewart, Brooke E Howitt, Marisa R Nucci, Glenn W Mccluggage

    Abstract:

    in recent years, a number of benign and malignant cervical glandular lesions exhibiting gastric differentiation have been described but premalignant gastric-type lesions have not been well characterized. We report a series of 9 cases of a rare form of cervical Adenocarcinoma in Situ (AIS) distinguis

  • Risk of persistent and recurrent cervical neoplasia following incidentally detected Adenocarcinoma in Situ
    American Journal of Obstetrics and Gynecology, 2017
    Co-Authors: Aime Munro, Jim Codde, Katrina Spilsbury, Nerida Steel, Colin J.r. Stewart, Stuart G. Salfinger, Ganendra R. Mohan, Yee Leung, James B. Semmens

    Abstract:

    Background Adenocarcinoma in Situ of the uterine cervix is a precursor to cervical Adenocarcinoma and may coexist with both Adenocarcinoma and high-grade squamous dysplasia (cervical intraepithelial neoplasia 2 and 3). Up to 60% of Adenocarcinoma in Situ lesions are detected incidentally following excisional biopsies performed for the treatment of cervical intraepithelial neoplasia 2/3. To date there are no data regarding risk factors for persisting or progressive cervical neoplasia in these patients. Objective We sought to investigate patient outcomes following incidentally detected cervical Adenocarcinoma in Situ after loop electrosurgical excision procedure or cold knife cone biopsy performed for the treatment of high-grade cervical intraepithelial neoplasia. Study Design We conducted a retrospective, population-based cohort study of Western Australian patients with an incidental diagnosis of Adenocarcinoma in Situ from 2001 through 2012. Primary outcomes were persistent or recurrent cervical intraepithelial neoplasia 2/3 and or Adenocarcinoma in Situ, and invasive Adenocarcinoma during follow-up ( Results The cohort comprised 298 patients, with 228 (76.5%) treated initially by loop electrosurgical excision procedure and 70 (23.5%) treated by cold knife cone biopsy. The mean age was 31.2 (range 18-68) years and the median length of follow-up was 2.4 (range 0.3-12.2) years. Overall, 11 (3.7%) patients had cervical intraepithelial neoplasia 2/3, 23 (7.7%) had Adenocarcinoma in Situ, and 3 (1.0%) had Adenocarcinoma diagnosed during the follow-up and surveillance periods. Age >30 years, pure Adenocarcinoma in Situ lesions, and larger lesions (>8 mm) were associated with a greater risk of disease persistence or recurrence. Conclusion Following the incidental detection of Adenocarcinoma in Situ, age >30 years, pure Adenocarcinoma in Situ lesions, and lesions >8 mm were significantly associated with disease persistence/recurrence. in younger women, incidentally detected Adenocarcinoma in Situ that coexists with cervical intraepithelial neoplasia 2/3 and is

  • Risk of persistent and recurrent cervical neoplasia following incidentally detected Adenocarcinoma in Situ.
    American journal of obstetrics and gynecology, 2016
    Co-Authors: Aime Munro, Jim Codde, Katrina Spilsbury, Nerida Steel, Colin J.r. Stewart, Stuart G. Salfinger, Ganendra R. Mohan, Yee Leung, James B. Semmens

    Abstract:

    Adenocarcinoma in Situ of the uterine cervix is a precursor to cervical Adenocarcinoma and may coexist with both Adenocarcinoma and high-grade squamous dysplasia (cervical intraepithelial neoplasia 2 and 3). Up to 60% of Adenocarcinoma in Situ lesions are detected incidentally following excisional biopsies performed for the treatment of cervical intraepithelial neoplasia 2/3. To date there are no data regarding risk factors for persisting or progressive cervical neoplasia in these patients.
    We sought to investigate patient outcomes following incidentally detected cervical Adenocarcinoma in Situ after loop electrosurgical excision procedure or cold knife cone biopsy performed for the treatment of high-grade cervical intraepithelial neoplasia.
    We conducted a retrospective, population-based cohort study of Western Australian patients with an incidental diagnosis of Adenocarcinoma in Situ from 2001 through 2012. Primary outcomes were persistent or recurrent cervical intraepithelial neoplasia 2/3 and or Adenocarcinoma in Situ, and invasive Adenocarcinoma during follow-up (<12 months) and surveillance (≥12 months) periods.
    The cohort comprised 298 patients, with 228 (76.5%) treated initially by loop electrosurgical excision procedure and 70 (23.5%) treated by cold knife cone biopsy. The mean age was 31.2 (range 18-68) years and the median length of follow-up was 2.4 (range 0.3-12.2) years. Overall, 11 (3.7%) patients had cervical intraepithelial neoplasia 2/3, 23 (7.7%) had Adenocarcinoma in Situ, and 3 (1.0%) had Adenocarcinoma diagnosed during the follow-up and surveillance periods. Age >30 years, pure Adenocarcinoma in Situ lesions, and larger lesions (>8 mm) were associated with a greater risk of disease persistence or recurrence.
    Following the incidental detection of Adenocarcinoma in Situ, age >30 years, pure Adenocarcinoma in Situ lesions, and lesions >8 mm were significantly associated with disease persistence/recurrence. in younger women, incidentally detected Adenocarcinoma in Situ that coexists with cervical intraepithelial neoplasia 2/3 and is <8 mm extent with clear margins may not require reexcision.
    Copyright © 2016 Elsevier inc. All rights reserved.